A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II

The optimal choice of biological agents after failure of anti‐tumour‐necrosis‐factor‐(TNF)α agent in Crohn’s disease (CD) is yet to be defined.

[1]  P. Austin.  Informing power and sample size calculations when using inverse probability of treatment weighting using the propensity score , 2021, Statistics in medicine.

[2]  B. Flourié,et al.  Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy , 2021, Alimentary pharmacology & therapeutics.

[3]  A. Alibrandi,et al.  Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases , 2021, JGH open : an open access journal of gastroenterology and hepatology.

[4]  A. Gutiérrez,et al.  How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data , 2021, Frontiers in Medicine.

[5]  L. Peyrin-Biroulet,et al.  Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. , 2020, Journal of Crohn's & colitis.

[6]  A. Amiot,et al.  Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study , 2020, Alimentary pharmacology & therapeutics.

[7]  J. Allegretti,et al.  Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification. , 2020, Inflammatory bowel diseases.

[8]  A. Magnano,et al.  OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD) , 2020 .

[9]  Philip Smith,et al.  Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease , 2020, Alimentary pharmacology & therapeutics.

[10]  S. Vermeire,et al.  Long‐term safety of vedolizumab for inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.

[11]  X. Calvet,et al.  Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry , 2020, Alimentary pharmacology & therapeutics.

[12]  D. D. de Jong,et al.  Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment , 2020, Alimentary pharmacology & therapeutics.

[13]  A. Amiot,et al.  The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor , 2020, Alimentary pharmacology & therapeutics.

[14]  A. Kaser,et al.  Crohn’s disease , 2020, Nature Reviews Disease Primers.

[15]  U. Kopylov,et al.  Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: A multicenter Israeli study , 2020, United European gastroenterology journal.

[16]  C. Selinger,et al.  Stigmatisation and resilience in inflammatory bowel disease , 2019, Internal and Emergency Medicine.

[17]  J. M. Nerín de la Puerta,et al.  Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort. , 2019 .

[18]  J. Stein,et al.  Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn’s Disease: Real-World Data from a German IBD Cohort , 2019, Journal of clinical medicine.

[19]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. , 2019, Journal of Crohn's & colitis.

[20]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.

[21]  R. Eliakim,et al.  Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  J. Gisbert,et al.  Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry , 2019, Alimentary pharmacology & therapeutics.

[23]  R. Nissinen,et al.  Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE) , 2019, Scandinavian journal of gastroenterology.

[24]  C. Stansfield,et al.  A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. , 2018, Journal of Crohn's & colitis.

[26]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[27]  A. Hart,et al.  Anti-TNF Therapy in Crohn’s Disease , 2018, International journal of molecular sciences.

[28]  G. D'Haens,et al.  Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease , 2018, Current Treatment Options in Gastroenterology.

[29]  A. Gottlieb,et al.  Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation , 2018, Journal of the American Academy of Dermatology.

[30]  M. Lebwohl,et al.  Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry , 2017, Journal of the American Academy of Dermatology.

[31]  P. Gibson,et al.  Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? , 2017, World journal of gastroenterology.

[32]  G. Kaplan,et al.  Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study , 2017, Inflammatory bowel diseases.

[33]  G. Kaplan,et al.  Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort , 2017, Alimentary pharmacology & therapeutics.

[34]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2) , 2016, Annals of the rheumatic diseases.

[35]  S. Vansteelandt,et al.  On regression adjustment for the propensity score , 2014, Statistics in medicine.

[36]  B. Scallon,et al.  Discovery and mechanism of ustekinumab , 2011, mAbs.

[37]  I. Koutroubakis,et al.  Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice. , 2010, Current drug targets.

[38]  C. J. van der Woude,et al.  The impact of biologics on health-related quality of life in patients with inflammatory bowel disease , 2009, Clinical and experimental gastroenterology.

[39]  Marco Vincenzo Lenti,et al.  Intestinal fibrosis. , 2019, Molecular aspects of medicine.

[40]  European Crohn’s and Colitis Organisation , 2019, The Grants Register 2022.

[41]  R. Eliakim,et al.  Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[42]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[43]  S. Brand,et al.  Malignant melanoma during ustekinumab therapy of Crohn's disease. , 2012, Inflammatory Bowel Diseases.